Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial

INTRODUCTION: Antineutrophil cytoplasm antibody-associated vasculitis (AAV) is a form of systemic vasculitis. The current standard induction therapy with the combination of high-dose glucocorticoids and cyclophosphamide or rituximab has high remission rates of 80%–90%. However, it is also associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuta, Shunsuke, Sugiyama, Takao, Umibe, Takeshi, Kaneko, Yuko, Amano, Koichi, Kurasawa, Kazuhiro, Nakaomi, Daiki, Hiraguri, Masaki, Hanaoka, Hideki, Sato, Yasunori, Ikeda, Kei, Nakajima, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778278/
https://www.ncbi.nlm.nih.gov/pubmed/29247107
http://dx.doi.org/10.1136/bmjopen-2017-018748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778278/
https://www.ncbi.nlm.nih.gov/pubmed/29247107
http://dx.doi.org/10.1136/bmjopen-2017-018748

Ejemplares similares